168 related articles for article (PubMed ID: 19076379)
1. Experimental therapeutic strategies for severe sepsis: mediators and mechanisms.
Parrish WR; Gallowitsch-Puerta M; Czura CJ; Tracey KJ
Ann N Y Acad Sci; 2008 Nov; 1144():210-36. PubMed ID: 19076379
[TBL] [Abstract][Full Text] [Related]
2. Novel strategies for the treatment of sepsis.
Riedemann NC; Guo RF; Ward PA
Nat Med; 2003 May; 9(5):517-24. PubMed ID: 12724763
[TBL] [Abstract][Full Text] [Related]
3. Regulatory role of C5a on macrophage migration inhibitory factor release from neutrophils.
Riedemann NC; Guo RF; Gao H; Sun L; Hoesel M; Hollmann TJ; Wetsel RA; Zetoune FS; Ward PA
J Immunol; 2004 Jul; 173(2):1355-9. PubMed ID: 15240730
[TBL] [Abstract][Full Text] [Related]
4. The enigma of sepsis.
Riedemann NC; Guo RF; Ward PA
J Clin Invest; 2003 Aug; 112(4):460-7. PubMed ID: 12925683
[TBL] [Abstract][Full Text] [Related]
5. Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1.
Chorny A; Delgado M
Am J Pathol; 2008 May; 172(5):1297-307. PubMed ID: 18385521
[TBL] [Abstract][Full Text] [Related]
6. Bench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department.
Sama AE; D'Amore J; Ward MF; Chen G; Wang H
Acad Emerg Med; 2004 Aug; 11(8):867-73. PubMed ID: 15289194
[TBL] [Abstract][Full Text] [Related]
7. Scientific and clinical challenges in sepsis.
Ulloa L; Brunner M; Ramos L; Deitch EA
Curr Pharm Des; 2009; 15(16):1918-35. PubMed ID: 19519432
[TBL] [Abstract][Full Text] [Related]
8. Current advances in sepsis and septic shock with particular emphasis on the role of insulin.
Das UN
Med Sci Monit; 2003 Aug; 9(8):RA181-92. PubMed ID: 12942044
[TBL] [Abstract][Full Text] [Related]
9. Advances in understanding sepsis.
Shimaoka M; Park EJ
Eur J Anaesthesiol Suppl; 2008; 42():146-53. PubMed ID: 18289433
[TBL] [Abstract][Full Text] [Related]
10. HMGB1, a potent proinflammatory cytokine in sepsis.
Huang W; Tang Y; Li L
Cytokine; 2010 Aug; 51(2):119-26. PubMed ID: 20347329
[TBL] [Abstract][Full Text] [Related]
11. Suppressive Effects of Ginsenoside Rh1 on HMGB1-Mediated Septic Responses.
Lee W; Cho SH; Kim JE; Lee C; Lee JH; Baek MC; Song GY; Bae JS
Am J Chin Med; 2019; 47(1):119-133. PubMed ID: 30630344
[TBL] [Abstract][Full Text] [Related]
12. Zingerone reduces HMGB1-mediated septic responses and improves survival in septic mice.
Lee W; Ku SK; Bae JS
Toxicol Appl Pharmacol; 2017 Aug; 329():202-211. PubMed ID: 28610995
[TBL] [Abstract][Full Text] [Related]
13. Sepsis: the inflammatory foundation of pathophysiology and therapy.
Li J; Carr B; Goyal M; Gaieski DF
Hosp Pract (1995); 2011 Aug; 39(3):99-112. PubMed ID: 21881397
[TBL] [Abstract][Full Text] [Related]
14. New therapies for sepsis.
Cunnington A; Nadel S
Curr Top Med Chem; 2008; 8(7):603-14. PubMed ID: 18473886
[TBL] [Abstract][Full Text] [Related]
15. Effects of dexamethasone on macrophage migration inhibitory factor production in sepsis.
Bruhn A; Verdant C; Vercruysse V; Su F; Vray B; Vincent JL
Shock; 2006 Aug; 26(2):169-73. PubMed ID: 16878025
[TBL] [Abstract][Full Text] [Related]
16. Immune-modulating interventions in critically ill septic patients: pharmacological options.
Toft P; Tønnesen E
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):491-501. PubMed ID: 22114858
[TBL] [Abstract][Full Text] [Related]
17. Characterization, epitope identification and mechanisms of the anti-septic capacity of monoclonal antibodies against macrophage migration inhibitory factor.
Zhang Y; Zeng X; Chen S; Zhang Z; Li P; Yi W; Huang H; Yao J; Li S; Hu C
Int Immunopharmacol; 2011 Sep; 11(9):1333-40. PubMed ID: 21571101
[TBL] [Abstract][Full Text] [Related]
18. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis.
Wang H; Liao H; Ochani M; Justiniani M; Lin X; Yang L; Al-Abed Y; Wang H; Metz C; Miller EJ; Tracey KJ; Ulloa L
Nat Med; 2004 Nov; 10(11):1216-21. PubMed ID: 15502843
[TBL] [Abstract][Full Text] [Related]
19. C5L2: a controversial receptor of complement anaphylatoxin, C5a.
Li R; Coulthard LG; Wu MC; Taylor SM; Woodruff TM
FASEB J; 2013 Mar; 27(3):855-64. PubMed ID: 23239822
[TBL] [Abstract][Full Text] [Related]
20. Role of high mobility group box 1 in inflammatory disease: focus on sepsis.
Bae JS
Arch Pharm Res; 2012 Sep; 35(9):1511-23. PubMed ID: 23054707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
